Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated Jun 10, 2025, titled "Press Release on US-FDA Compliance status for OneSource".
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.5 pts more than Nifty Smallcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
OneSource Specialty Pharma's flagship drug-device combination facility in Bangalore has received a 'Voluntary Action Indicated' (VAI) classification from the USFDA, confirming its continued compliance. The USFDA had inspected the facility from March 20 to March 28, 2025, and issued a Form 483 with four observations. After the company submitted a comprehensive response, the agency classified the outcome as VAI, officially closing the inspection. This facility is central to the company's manufacturing of drug-device combinations, biologics drug substances, and complex injectables, and is expected to support partner launches of key GLP-1 products in late FY26.
This is a positive outcome for shareholders, as the VAI classification means no mandatory corrective action is required from the USFDA, removing a regulatory overhang. It strengthens OneSource's credibility as a compliant CDMO partner and supports upcoming commercial launches, which could positively influence the stock price.